Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase-Reference-Cited by-同舟云学术

Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase

Published:2023-06 Issue:6 Volume:86 Page:622-625
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Wan Eric Yuk Fai,Wang Boyuan,Mathur Sukriti,Chan Cheyenne I. Ying,Yan Vincent Ka Chun,Lai Francisco Tsz Tsun,Chui Celine Sze Ling,Li Xue^ORCID,Wong Carlos King Ho,Li Philip Hei,Lau Chak Sing,Wong Ian Chi Kei,Chan Esther Wai Yin

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference10 articles.

1. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study;Evans;J Infect,2023

2. A living WHO guideline on drugs for covid-19;Agarwal;BMJ,2020

3. Long-COVID treatments: why the world is still waiting;Ledford;Nature,2022

4. Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series;Wan;Lancet Healthy Longev,2022

5. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study;Wan;Lancet Infect Dis,2022

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis;Tungs' Medical Journal;2024-08-08

2. Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity;Heliyon;2024-08

3. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis;Journal of Infection;2024-08

4. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study;Diagnostic Microbiology and Infectious Disease;2024-08

5. Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression;PLOS ONE;2024-06-06